Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.
The authors performed an open, randomized trial in patients with inclusion body myositis comparing 1) 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group) with 2) 12-month MTX treatment preceded by 7 days of IV anti-T-lymphocyte immunoglobulin treatment (ATG group). Eleven patients were randomized; 10 patients completed 12 months follow-up. Myometry showed that patients in the ATG group (n = 6) increased in mean muscle strength by 1.4% compared with the MTX group (n = 5), whose muscle strength decreased by 11.1% (p = 0.021).
Lindberg
C
C
Department of Neurology, Sahlgrenska University Hospital/Molndal, Sahlgrenska NeuroMuscular Center, Gothenburg, Sweden. christopher.lindberg@vgregion.se
Trysberg
E
E
Tarkowski
A
A
Oldfors
A
A
D000368:Aged; D000369:Aged, 80 and over; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009119:Muscle Contraction; D018979:Myositis, Inclusion Body / Q000628:therapy*; D010865:Pilot Projects; D011446:Prospective Studies; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D008727:Methotrexate